Drugs / vedicitumomab
vedicitumomab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898373 | Jun 2023 → Jun 2025 | salivary gland cancer | Peking Union Medical College | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vedicitumomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898373 ↗ |
| Known as | Edisil | “vedicitumomab (Edisil, RC48）” NCT05898373 ↗ |
| Known as | RC48 | “vedicitumomab (Edisil, RC48）” NCT05898373 ↗ |
| Action | Inhibit | “anti-HER2” NCT05898373 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent” NCT05898373 ↗ |
| Route | Intravenous | “vedicitumomab monotherapy (2.5 mg/kg, intravenous, Q2w)” NCT05898373 ↗ |